CYP-associated drug-drug interactions: A mission accomplished?
Arch Toxicol
; 94(11): 3931-3934, 2020 11.
Article
in En
| MEDLINE
| ID: mdl-33025068
ABSTRACT
On the basis of official Finnish Medicines Authority (Fimea)-approved drug monographs, less than half of the approved small-molecule drugs between 2007 and 2016 were substrates, inhibitors or inducers of CYP enzymes, predominantly of CYP3A4. No significant unexpected, life-threatening, CYP-associated drug-drug interactions (CYP-DDIs) of newly approved drug entities have been observed in the last 10-15 years. The present analysis seems to suggest that tools to study and predict potentially significant CYP-DDIs are working and efficient.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Interactions
/
Cytochrome P-450 CYP3A
/
Cytochrome P-450 CYP3A Inducers
/
Cytochrome P-450 CYP3A Inhibitors
Type of study:
Risk_factors_studies
Limits:
Animals
/
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Arch Toxicol
Year:
2020
Document type:
Article